TNF-α拮抗剂对寻常型银屑病患者血管炎症的影响:随机安慰剂对照研究
这项随机双盲多中心研究纳入107例寻常型银屑病患者,评估阿达木单抗对血管炎症的影响。第16周时,阿达木单抗组与安慰剂组在升主动脉和颈动脉的血管壁靶本底比(TBR)变化上无差异。阿达木单抗治疗52周后,升主动脉TBR无显著变化,但颈动脉TBR较治疗开始时轻度增加。
要点
- 阿达木单抗治疗16周未改善升主动脉或颈动脉血管炎症。
- 阿达木单抗治疗52周后颈动脉TBR较基线轻度增加。
- 需进一步研究TNF-α拮抗剂对银屑病血管炎症的长期影响。
核心结论
- 阿达木单抗与安慰剂相比,16周内未显著改变银屑病患者的血管炎症。
- 阿达木单抗治疗52周后颈动脉血管炎症轻度增加。
研究设计与样本
- 随机、双盲、多中心研究,共纳入107例寻常型银屑病患者。
- 患者按1:1随机分配至阿达木单抗组(治疗52周)或安慰剂组(治疗16周后转为阿达木单抗治疗52周)。
- 采用正电子发射断层扫描-计算机断层扫描评估血管炎症。
主要发现
- 第16周时,升主动脉TBR变化:阿达木单抗组0.002(95%CI -0.048至0.053),安慰剂组-0.002(95%CI -0.053至0.049),P=0.916。
- 第16周时,颈动脉TBR变化:阿达木单抗组0.031(95%CI -0.005至0.066),安慰剂组0.018(95%CI -0.019至0.055),P=0.629。
- 阿达木单抗治疗52周后,升主动脉TBR较治疗开始变化-0.006(95%CI -0.049至0.038),P=0.796。
- 阿达木单抗治疗52周后,颈动脉TBR较治疗开始变化0.027(95%CI 0.000至0.054),P=0.046。
临床怎么用
- 对于寻常型银屑病患者,TNF-α拮抗剂治疗16周未显示对血管炎症的改善作用。
- 长期使用阿达木单抗时需关注颈动脉血管炎症的潜在变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vascular inflammation is increased in patients with psoriasis. This randomized, double-blind, multicenter study evaluated the effects of tumor necrosis factor-α antagonist adalimumab on vascular inflammation in patients with psoriasis. A total of 107 patients were randomized (1:1) to receive adalimumab for 52 weeks or placebo for 16 weeks followed by adalimumab for 52 weeks. Vascular inflammation was assessed with positron emission tomography-computed tomography. There were no differences in the change from baseline in vessel wall target-to-background ratio (TBR) from the ascending aorta (primary endpoint) (adalimumab: TBR = 0.002, 95% confidence interval [CI] = -0.048 to 0.053; placebo: TBR = -0.002, 95% CI = -0.053 to 0.049; P = 0.916) and the carotids (adalimumab: TBR = 0.031, 95% CI = -0.005 to 0.066; placebo: TBR = 0.018, 95% CI = -0.019 to 0.055; P = 0.629) at week 16 between adalimumab and placebo. After 52 weeks of treatment with adalimumab there was no significant change from start of treatment in TBR from the ascending aorta (TBR = -0.006, 95% CI = -0.049 to 0.038; P = 0.796), but there was an increase in TBR in carotids (TBR = 0.027, 95% CI = 0.000 to 0.054; P = 0.046). This study showed no difference over 16 weeks in vascular inflammation in patients treated with a tumor necrosis factor-α antagonist or placebo and a modest increase in vascular inflammation in carotids after 52 weeks of treatment with adalimumab.
引用
- Bissonnette R, Harel F, Krueger JG, et al. TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. J Invest Dermatol. 2017. PMID: 28286061. doi:10.1016/j.jid.2017.02.977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。